Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487405 · ClinicalTrials.gov registry record
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
A clinical trial, sponsored by Aspira Women's Health.
- Terminated
- Registry status
- 721
- Enrollment target
NCT04487405 is a clinical trial that was terminated before completion, run by Aspira Women's Health. The registered enrollment target is 721 participants.
The verdict
NCT04487405 was terminated before completion, sponsored by Aspira Women's Health.
- TERMINATED
- Registry status
- 721 participants
- Enrollment target
Study Summary
The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
Interventions
- DEVICE OVAnex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 721 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04487405
The ClinicalTrials.gov registry entry for NCT04487405 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 721 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aspira Women's Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OVAnex is the first listed.
NCT04487405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04487405 about?
NCT04487405 is a clinical study titled "A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants". The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
What is the current status of trial NCT04487405?
This trial is currently terminated. The enrollment target is 721 participants. The study started on 2020-06-25. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04487405?
The interventions under investigation include: OVAnex (DEVICE).
Who is sponsoring clinical trial NCT04487405?
This trial is sponsored by Aspira Women's Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.